Business
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumat...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Abstract covering Phase 2 osteoarthritis trial results accepted as a late-breaking submission\n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Nov. 1, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced late-breaking acceptance of the Company's abstract for a poster presentation at the 2023 Annual Meeting of the American College of Rheumatology.\n \n \n The meeting is being held at the\n \n San Diego\n \n Convention Center from\n \n November 10-15, 2023\n \n , in\n \n San Diego, CA.\n \n Late-breaking acceptance is typically reserved for important clinical trial results and groundbreaking science. Eupraxia's Chief Scientific Officer,\n \n Amanda Malone\n \n , will present the poster highlighting the Company's Phase\n \n 2b\n \n data for EP-104IAR. Key highlights from the study include:\n \n \n \n Meeting the primary endpoint and three key secondary endpoints;\n \n \n Data supporting clinically meaningful and durable pain relief; and\n \n \n Pharmacokinetic and safety data that support the potential for chronic and bilateral dosing.\n \n \n \n \"We were pleased to be accepted as a late-breaking abstract based on the clinically meaningful data from our Phase\n \n 2b\n \n trial in knee osteoarthritis as we work to highlight the findings with clinicians, key opinion leaders and the broader pharmaceutical industry,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"As we focus on highlighting our strong Phase\n \n 2b\n \n results, we are also continuing to work toward advancing EP-104IAR into late-stage clinical testing to further demonstrate the potential of this product candidate in patients with osteoarthritis of the knee.\"\n \n \n \n Poster Title:\n \n EP-104IAR (Extended-Release Fluticasone Propionate fo...